Biosimilar Pathway Evaluation

A technical and strategic assessment of whether — and how — a biosimilar version of a specific biologic can be developed, manufactured, and brought to market.

What It Is

Biosimilars are the most direct route to reducing biologic drug costs. But the path from reference product to approved biosimilar is neither simple nor guaranteed. This evaluation examines whether a biosimilar opportunity is real: technically feasible, economically viable, and strategically sound.

We assess the molecular complexity, manufacturing requirements, regulatory landscape, and competitive dynamics to give a clear go/no-go recommendation.

What You Get

Technical feasibility report — molecular characterization challenges and analytical comparability requirements
Manufacturing assessment — cell line development, process design, and scale-up considerations
Regulatory pathway map — requirements by jurisdiction, estimated timelines, and data package scope
Market analysis — reference product revenue, patent expiry landscape, and competitive biosimilar pipeline
Economic model — development cost estimate, break-even analysis, and pricing strategy options

Who It Serves

Generic and biosimilar manufacturers evaluating new product candidates
Biotech investors assessing biosimilar opportunities
Government agencies developing domestic biosimilar production capabilities
Healthcare systems exploring cost-reduction strategies through biosimilar procurement